Cerebrolysin

Cerebrolysin is described as a multicomponent peptide preparation derived from porcine brain tissue that contains bioactive neuropeptides and amino acids under ~10 kDa. The protocol states that this low molecular weight enables passage across the blood–brain barrier, where Cerebrolysin can exert neurotrophic-like effects similar to endogenous growth factors such as NGF and BDNF. Mechanistically, it is framed as supporting neuronal survival and recovery pathways rather than acting as a single defined peptide agonist. The page summarizes preclinical evidence showing reduced infarct size and improved functional recovery in ischemia models, and it notes that human trials have studied Cerebrolysin in stroke, dementia, and traumatic brain injury with mixed efficacy outcomes but generally favorable tolerability. Overall, the ‘how it works’ narrative is that Cerebrolysin delivers a spectrum of neuroactive peptides that can promote neuroprotection and neurorepair signals, with safety in short-term use generally described as acceptable.